Cas:34215-57-1 3,3′-Dioctadecyloxacarbocyanine perchlorate manufacturer & supplier

We serve Chemical Name:3,3′-Dioctadecyloxacarbocyanine perchlorate CAS:34215-57-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3,3'-Dioctadecyloxacarbocyanine perchlorate

Chemical Name:3,3′-Dioctadecyloxacarbocyanine perchlorate
CAS.NO:34215-57-1
Synonyms:DiO DiOC18(3);NK 3045;D275;DiOC18(3) [3,3′-Dioctadecyloxacarbocyanine perchlorate];3,3′-Dioctadecyloxacarbocyanine perchlorate
Molecular Formula:C53H85ClN2O6
Molecular Weight:881.70500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:109.36000
Exact Mass:880.61000
LogP:16.78030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1479
Packing Group:III


Contact us for information like DiO DiOC18(3) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,3′-Dioctadecyloxacarbocyanine perchlorate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DiOC18(3) [3,3′-Dioctadecyloxacarbocyanine perchlorate] Use and application,3,3′-Dioctadecyloxacarbocyanine perchlorate technical grade,usp/ep/jp grade.


Related News: The results provided a formulation amenable to two dosage strengths by applying a proportional dosing weight method.” The product is currently in late-stage development with the New Drug Application filing expected in late 2021. (5-formylfuran-2-yl)methyl pentadecanoate manufacturers “In the past few years, the pharmaceutical industry has seen rapid growth driven by the growth of small molecules’ innovations, complex APIs and the increasing need to optimize available resources. 2-Oxo-2,3,4,4a,5,6,7,8-octahydro-4a-naphthalincarbonsaeureaethylester suppliers McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. (4’S,5’S)-1′,3′-dimethyl-4′,5′-diphenyl-3,3aS,4,5,6aS-hexahydro-1-phenylmethylspiro[1H-cyclopent[c]isoxazole-4,2′-imidazolidine] vendor & factory.